Pangea Laboratory, an accredited leader in next-generation sequencing and molecular diagnostics, has announced a strategic collaboration with global biotech firm Gene Solutions to validate AI-powered liquid biopsy assays for cancer detection, characterization, and monitoring in US clinical settings. Once validated, the tests are expected to be offered as laboratory-developed tests (LDTs). 

Under the agreement, Pangea will use its integrated validation platform and regulatory expertise to oversee analytical and clinical validation of Gene Solutions’ multi-omics technologies.  

Gene Solutions will provide technical support, standard operating procedures, and funding from its CAP-accredited laboratories in Singapore and Vietnam. Following validation, the tests could be performed at Pangea’s Irvine facility under CLIA/CAP standards, bringing advanced cancer detection and monitoring tools closer to US patients. 

“Pangea is pleased to support the advancement of SPOT-MAS and K-4CARE in the U.S. market,” said John Moore, CEO of Pangea Laboratory.  

“Our mission is to develop and enable next-generation diagnostics that provide patients answers sooner, and these assays are complementary to Pangea's Bladder CARE test for the early detection of bladder cancer. Our validation platform is purpose-built for innovative LDTs, and we look forward to helping bring these breakthrough technologies to patients and providers.” 

Hoa Giang, Co-founder and Chief Data Science Officer of Gene Solutions, added, “Partnering with Pangea gives us a precision validation engine in the US. By combining our AI-driven multi-omics innovations with Pangea's deep scientific expertise and proven track record in CLIA/CAP environments, we're positioned to deliver affordable, advanced cancer detection and monitoring tools.”